B - Summary of pharmacokinetic (PK) and pharmacodynamic (PD) interactions of interest concerning non-immunosuppressive anticancer drugs and potential COVID-19 treatments.
No interaction driven by other cytochromes were found. Red arrows are for interactions relying on clinically significant data. Orange arrows are for interactions relying on in vitro data for pharmacokinetic interactions. Cytochromes involved in the drug interaction were specified. Substrates for which induction but not inhibition could lead to significant interaction are between brackets. When the interaction modifies the pharmacokinetics of the anticancer drug, the arrow was on the bottom-left. Antiviral exposition prediction is on the top-right. Red boxes are for anticancer drugs with known Torsade-de-Pointes risk and high risk of renal and liver toxicities. Orange boxes are for anticancer drugs prolonging QT without known Torsade-de-Pointes risk and moderate risk for renal and liver toxicities.
Data from FDA labels [4] were retrieved for drug metabolism, QT prolongation, and nephrotoxicity. Livertox database was used for hepatotoxicity[5].